Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Nanovation Therapeutics Inc. is currently navigating 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 3 distinct examiners and 3 distinct art units. This distribution indicates that each application is receiving an independent review from a different technical expert. For patent practitioners, this decentralized workload means that a success or failure in one case may not necessarily influence the outcomes of the others.
AZPURU, CARLOS A is identified as the busiest examiner for the portfolio, managing 1 busiest examiner pending action. Since this 1 busiest examiner pending action represents only a portion of the total 3 pending office actions, the company's prosecution strategy must be adapted for multiple individuals. The presence of 3 distinct examiners suggests that the company is engaging with a variety of examination styles and interpretations within the Biotechnology & Pharmaceuticals sector.
The involvement of 3 distinct art units further highlights the technical breadth of the company's current filings. Each of these groups may have its own procedural nuances and internal guidelines. Consequently, the prosecution team must remain flexible and prepared to address the specific requirements of each unit to advance the 3 pending office actions toward allowance. This variety in the 3 distinct examiners ensures that the portfolio's progress is not overly dependent on the discretion of a single patent office official.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AZPURU, CARLOS A | 1 | 83.8% | +10.8% |
| BRADY, KRISTEN WEEKS | 1 | 50.0% | +0.0% |
| LIPPERT, JOHN WILLIAM | 1 | 59.2% | +39.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18650569 | MRNA DELIVERY METHOD AND COMPOSITION THEREOF | AZPURU, CARLOS A | — |
| 18442431 | Method for the Synthesis of Ionizable Lipids Using a Doubly Alkylated Intermediate | BRADY, KRISTEN WEEKS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18564780 | Method for Producing an Ionizable Lipid | LIPPERT, JOHN WILLIAM | 19d |
| 18650569 | MRNA DELIVERY METHOD AND COMPOSITION THEREOF | AZPURU, CARLOS A | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1692 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18650569 | MRNA DELIVERY METHOD AND COMPOSITION THEREOF | AZPURU, CARLOS A | 1617 | §103§112Other | Non-Final OA | — | Pending | Apr 30, 2024 |
| 18442431 | Method for the Synthesis of Ionizable Lipids Using a Doubly Alkylated Intermediate | BRADY, KRISTEN WEEKS | 1692 | §101§112 | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18564780 | Method for Producing an Ionizable Lipid | LIPPERT, JOHN WILLIAM | 1615 | §103 | Final Rejection | 19d | Pending | Nov 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNanovation Therapeutics Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Carlos A Azpuru has the most, with 1 of Nanovation Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
